| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalaris Therapeutics, Inc. (KLRS) has 2 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. KLRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 2.22M | $10.50M | - | |
| CFO | 235.0K | $1.11M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 10, 2025 | Sinha Vikas84 | See Remarks | Sell | 979 | $0.44 | $430.86 | - | -27.6% | -3.2% | |
| Nov 19, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 554 | $0.55 | $303.87 | -0.8% | -25.6% | -48.1% | |
| Nov 19, 2024 | Sinha Vikas84 | See Remarks | Sell | 3,186 | $0.55 | $1,747.52 | -0.3% | -25.6% | -48.1% | |
| Nov 19, 2024 | Miller Edward82 | General Counsel | Sell | 432 | $0.55 | $236.95 | -0.2% | -25.6% | -48.1% | |
| Nov 19, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 8,706 | $0.55 | $4,775.24 | -1.2% | -25.6% | -48.1% | |
| Nov 5, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 10,609 | $0.86 | $9,175.72 | -1.4% | -57.0% | -78.0% | |
| Nov 5, 2024 | Miller Edward82 | General Counsel | Sell | 2,272 | $0.86 | $1,965.05 | -1.1% | -57.0% | -78.0% | |
| Nov 5, 2024 | Sinha Vikas84 | See Remarks | Sell | 5,136 | $0.86 | $4,442.13 | -0.4% | -57.0% | -78.0% | |
| Nov 5, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 1,655 | $0.86 | $1,431.41 | -2.3% | -57.0% | -78.0% | |
| Oct 22, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 965 | $0.77 | $746.29 | -0.7% | -47.6% | -75.5% |